120. Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (expec10v) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study
Open Forum Infectious Diseases（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要